Hunan Province Tumor Hospital
2 clinical trials · 2 recruiting · OTHER
Trials by Hunan Province Tumor Hospital
RECRUITINGNCT06183762
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical...
Sponsor: Hunan Province Tumor HospitalEnrolling: 2001 location
Advanced Lung Cancer
RECRUITINGPhase 2NCT05379803
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated...
Sponsor: Hunan Province Tumor HospitalEnrolling: 401 location
Non-Small Cell Lung Cancer